The U.S. FDA has given its nod to Seattle Genetics for its Tukysa (tucatinib) for advanced unresectable or metastatic HER2-positive breast cancer
Genetics
Tukysa (tucatinib) is a tyrosine kinase inhibitor of the HER2 protein, administered orally in combination with chemotherapy agents trastuzumab and capecitabine to adults with metastatic HER2+ breast cancer. The drug has shown inhibitory properties in phosphorylation of HER2 and HER3 under in-vitro lab studies. The study observed a significant reduction in the risk of cancer progression or death (PFS) compared to patients who received trastuzumab and capecitabine alone.
The drug came is a collaborative pr...
